Skip to main content

Table 1 Patient characteristics enrolled in this study (nā€‰=ā€‰97)

From: Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy

Ā 

Number

%

Sex

Ā Ā 

ā€ƒā€‰Male

63

64.9

ā€ƒā€‰Female

34

35.1

Age, meanā€‰Ā±ā€‰SD

66.9ā€‰Ā±ā€‰9.0

Ā 

Histology

Ā Ā 

ā€ƒā€‰Adenocarcinoma

65

67.0

ā€ƒā€‰Squamous cell carcinoma

17

17.5

ā€ƒā€‰Large cell carcinoma

8

8.2

ā€ƒā€‰Adenosquamous carcinoma

2

2.1

ā€ƒā€‰Pleomorphic carcinoma

5

5.2

Tumor differentiation

Ā Ā 

ā€ƒā€‰Well

29

29.9

ā€ƒā€‰Moderate

29

29.9

ā€ƒā€‰Poor

39

40.2

Nodal status

Ā Ā 

ā€ƒā€‰N0

56

57.7

ā€ƒā€‰N1

19

19.6

ā€ƒā€‰N2

22

22.7

Pathological stage

Ā Ā 

ā€ƒā€‰IA

10

10.3

ā€ƒā€‰IB

32

33.0

ā€ƒā€‰IIAā€‰+ā€‰IIB

27

27.8

ā€ƒā€‰IIIA

28

28.9

Chemotherapy regimen

Ā Ā 

ā€‚Platinum-based agent

51

52.6

ā€ƒā€‰CBDCAā€‰+ā€‰paclitaxel

35

Ā 

ā€ƒā€‰CBDCAā€‰+ā€‰gemcitabine

7

Ā 

ā€ƒā€‰CBDCAā€‰+ā€‰S1

5

Ā 

ā€ƒā€‰CDDPā€‰+ā€‰others

4

Ā 

ā€‚Oral tegafur agent

46

47.4

ā€ƒā€‰UFT

37

Ā 

ā€ƒā€‰S1

9

Ā 
  1. SD: standard deviation; CDDP: cisplatin; CBDCA: carboplatin; UFT: tegafur-uracil.